SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03595644

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Trial.

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with a targeted agent such as gefitinib, erlotinib and icotinib.

NCT03595644 Stage IV Non-small Cell Lung Cancer
MeSH:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO:Neoplasm of the lung Non-small cell lung carcinoma

2 Interventions

Name: SBRT+TKI

Description: Received SBRT after three months after EGFR-TKI treatment
Type: Radiation
Group Labels: 1

SBRT+TKI

Name: TKI

Description: Received EGFR-TKI treatment
Type: Drug
Group Labels: 1

TKI


Primary Outcomes

Description: progression-free survival

Measure: PFS

Time: 2 years

Secondary Outcomes

Description: overall survival

Measure: OS

Time: 3 year

Purpose: Treatment

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 L858R

exon 19 deletion or exon 21 L858R) 10. --- L858R ---



HPO Nodes


HPO: